GLP-1 Drugs for Kids: What Pediatric Obesity Trials Really Show

Last Updated: January 2025

Childhood obesity affects 19.7% of US children and adolescents aged 2-19 years, according to CDC 2022 data—a prevalence that has nearly tripled since the 1970s. For decades, the only FDA-approved pharmacological tools for this population were behavioral interventions and, in extreme cases, bariatric surgery. That changed in December 2022 when the FDA approved semaglutide (Wegovy) for adolescents aged 12 and older with obesity, marking the first major glucagon-like peptide-1 receptor agonist (GLP-1 RA) authorization for pediatric weight management. The move followed clinical trial data showing weight reductions previously unseen with lifestyle modification alone, but it also ignited debate about medicating children for a condition many clinicians still view as primarily behavioral.

The approval wasn't arbitrary. It stemmed from the STEP TEENS trial, published in the New England Journal of Medicine in 2022, which enrolled 201 adolescents aged 12-18 with obesity (BMI ≥95th percentile for age and sex). Participants receiving once-weekly subcutaneous semaglutide 2.4 mg demonstrated a mean BMI reduction of 16.1% at 68 weeks, compared to 0.6% in the placebo group. That's a 15.5 percentage-point difference—clinically meaningful by any standard. More striking: 73% of semaglutide-treated adolescents achieved at least 5% BMI reduction, versus 18% on placebo.

Dr. Aaron Kelly, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota and lead author of STEP TEENS, stated in the study: "The degree of BMI reduction observed with semaglutide was greater than what we typically see with intensive lifestyle intervention alone." That's an understatement. Traditional behavioral programs for pediatric obesity produce average BMI reductions of 1-3% at best, and maintaining those losses beyond 12 months is rare.

Liraglutide: The First-Mover with Modest Results

Before semaglutide, liraglutide (Saxenda) held FDA approval for adolescents 12 and older starting in 2020, based on a trial of 251 participants. The results were less impressive: mean BMI reduction of 4.5% versus 0.4% increase with placebo at 56 weeks. Still meaningful, but the effect size paled compared to what came next. Liraglutide requires daily subcutaneous injection at 3.0 mg, a higher frequency and lower efficacy profile that made it a tough sell for adolescents already navigating the social stigma of obesity.

The pharmacological difference matters. Semaglutide has a longer half-life (approximately 1 week versus 13 hours for liraglutide), enabling once-weekly dosing and sustained GLP-1 receptor activation. This translates to better appetite suppression, slower gastric emptying, and crucially for adherence, fewer injection days. In adult populations, semaglutide consistently outperforms liraglutide by 5-8 percentage points in total body weight reduction. The adolescent data follows the same pattern.

Tirzepatide: Dual Agonist, No Pediatric Approval Yet

Tirzepatide (Mounjaro/Zepbound), a dual GLP-1/GIP receptor agonist, dominates adult obesity treatment with weight losses reaching 20.9% at 72 weeks in the SURMOUNT-1 trial. But as of January 2025, it lacks FDA approval for pediatric use. Eli Lilly launched a Phase 3 adolescent trial in late 2023, mirroring the STEP TEENS design with participants aged 12-17. Results aren't public yet, though given tirzepatide's adult superiority—head-to-head studies show 5-7 percentage-point greater weight loss versus semaglutide—expectations run high.

Here's the regulatory bottleneck: pediatric drug approval requires separate safety and efficacy trials, even when adult data is robust. The FDA won't extrapolate from grown-up metabolism to adolescent physiology without direct evidence. Reasonable from a safety standpoint, frustrating from a clinical access perspective. Adolescents with severe obesity who've exhausted behavioral options currently face a choice between semaglutide and liraglutide, while their parents read headlines about tirzepatide's superior adult outcomes.

Safety Profile: Mostly GI, Some Concerns

Adverse events in adolescent GLP-1 trials mirror adult patterns. Gastrointestinal effects dominate: nausea (44% with semaglutide versus 19% placebo in STEP TEENS), vomiting, diarrhea, constipation. Most cases were mild to moderate and decreased after the first 8-12 weeks as titration completed. Serious adverse events occurred in 5.9% of semaglutide-treated adolescents versus 5.9% of placebo—essentially equivalent, though the types differed. Three semaglutide participants discontinued due to GI intolerance.

The bigger question: growth and development. Adolescents are still maturing—skeletal growth, hormonal changes, brain development. Do GLP-1 drugs interfere? STEP TEENS tracked height velocity and found no difference between groups. Participants grew normally. Gallbladder events, a known GLP-1 class effect in adults due to bile stasis, appeared in 1% of adolescent semaglutide users. Not zero, but rare. One case of acute pancreatitis occurred in the semaglutide group, a complication that prompts black-box discussions despite unclear causality.

What about psychological effects? Adolescent obesity correlates strongly with depression, anxiety, and poor self-esteem. Weight loss typically improves these metrics. STEP TEENS used the Patient Health Questionnaire-9 and found modest improvements in depressive symptoms among semaglutide users compared to placebo, though the trial wasn't powered for mental health endpoints. Some clinicians worry about eating disorder risk—could appetite suppression trigger restrictive behaviors? Fair concern, but screening protocols excluded adolescents with active eating disorders, and no new cases emerged during the trial. Still, real-world monitoring matters more than controlled trial environments.

Efficacy Beyond BMI

Weight reduction is the headline, but metabolic improvements matter more long-term. Adolescents with obesity face elevated cardiovascular risk, prediabetes, fatty liver disease, and obstructive sleep apnea. STEP TEENS measured cardiometabolic markers: semaglutide users saw improvements in HbA1c (-0.3 percentage points), fasting insulin (-11.7 µIU/mL), and triglycerides. Systolic blood pressure dropped by 5.4 mmHg versus 0.3 mmHg in placebo.

These aren't cosmetic changes. Type 2 diabetes in adolescents, once rare, now accounts for up to 45% of new pediatric diabetes diagnoses in some populations. The TODAY study followed adolescents with type 2 diabetes and found rapid beta-cell failure and early microvascular complications—worse outcomes than adult-onset diabetes. If GLP-1 drugs prevent progression from obesity to type 2 diabetes in high-risk teens, the public health calculus shifts dramatically.

Who Gets Access?

FDA approval doesn't guarantee availability. Insurance coverage for pediatric obesity medications remains patchy. Many commercial plans exclude GLP-1 drugs for weight management, period. Medicaid coverage varies by state—some cover semaglutide for adolescents, others don't. Monthly costs run $1,000-$1,300 without insurance. That's prohibitive for most families, particularly those in demographic groups with the highest obesity prevalence: Hispanic (26.2%) and non-Hispanic Black (24.8%) youth, per CDC data.

The American Academy of Pediatrics released 2023 guidelines recommending pharmacotherapy for adolescents 12 and older with obesity, integrated with behavioral and nutritional support. Note "integrated with," not "instead of." No trial tested GLP-1 monotherapy without lifestyle intervention, and no clinician should prescribe it that way. The STEP TEENS protocol included monthly counseling on diet and physical activity. Real-world adherence to that bundled approach is unknown.

Drug	FDA Approval (Pediatric)	Dosing Frequency	Mean BMI Reduction	Trial Duration
Liraglutide (Saxenda)	2020, age 12+	Daily injection	4.5% vs 0.4% placebo	56 weeks
Semaglutide (Wegovy)	2022, age 12+	Weekly injection	16.1% vs 0.6% placebo	68 weeks
Tirzepatide (Zepbound)	Not approved (trial ongoing)	Weekly injection	TBD (adult: 20.9%)	TBD

Duration of Treatment: The Unasked Question

Here's what pediatric trials don't answer: how long should adolescents stay on GLP-1 drugs? STEP TEENS ran 68 weeks—just over a year. Extension studies in adults show rapid weight regain after discontinuation. A 2022 study in Diabetes, Obesity and Metabolism found that adults stopping semaglutide regained two-thirds of lost weight within one year. Adolescent data doesn't exist yet, but physiology suggests similar rebound.

This raises an uncomfortable possibility: lifelong pharmacotherapy starting in adolescence. We have decades of safety data on antihypertensives and statins for chronic disease management. We have less than three years for pediatric GLP-1 use. The longest liraglutide pediatric trial tracked participants for 56 weeks. What happens at five years? Ten? Unknown.

Opponents argue we're medicalizing a behavioral problem, creating pharmaceutical dependence instead of addressing root causes—food environment, poverty, lack of safe spaces for physical activity. Fair points, but they ignore the reality facing a 14-year-old with BMI in the 99th percentile, prediabetes, and orthopedic complications. That teenager doesn't have time for policy changes to fix the food system. They need intervention now.

The Regulatory Gatekeeping Problem

FDA's requirement for separate pediatric trials delays access to potentially beneficial treatments. Tirzepatide's adult efficacy data is overwhelming—multiple trials across thousands of participants. Yet adolescents with severe obesity must wait for bespoke trials to conclude before accessing a drug their parents can get prescribed tomorrow. The precautionary principle protects against harm, but it also guarantees harm through delay.

Compare this to other therapeutic areas. Oncology uses "extrapolation frameworks" to approve pediatric cancer drugs based primarily on adult data when disease biology is similar. Obesity physiology isn't radically different between a 17-year-old and an 18-year-old. The cutoff is administrative, not biological. Some pediatric endocrinologists prescribe tirzepatide off-label already, relying on adult data and clinical judgment. That creates access inequality—families with well-connected physicians and willingness to navigate insurance denials get it, others don't.

Comparative Effectiveness in Real-World Practice

Randomized trials have internal validity but limited external generalizability. A 2024 retrospective cohort study from the Cleveland Clinic, published in Obesity, analyzed outcomes for 621 adults receiving either tirzepatide